XSHE
000623
Market cap3.14bUSD
Jul 09, Last price
17.83CNY
1D
0.73%
1Q
-2.25%
Jan 2017
-25.21%
Name
Jilin Aodong Pharmaceutical Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||